Mitteilung über Geschäfte von Führungspersonen nach §15a WpHG Directors’-Dealings-Mitteilung übermittelt durch die DGAP. Für den Inhalt der Mitteilung ist der Mitteilungspflichtige verantwortlich. ————————————————————————— Angaben zum Mitteilungspflichtigen Name: Dr. Taapken Vorname: Thomas Funktion: Geschäftsführendes Organ Angaben zum mitteilungspflichtigen Geschäft Bezeichnung des Finanzinstruments: Aktie ISIN/WKN des Finanzinstruments: DE000A1K0516 Geschäftsart: Kauf Datum: 28.03.2014 Kurs/Preis: 5,336 Währung: EUR Stückzahl: […]
Year: 2014
28. March 2014
Epigenomics AG: Epigenomics AG Publishes 2013 Annual Report and Provides Outlook for the Year 2014
Epigenomics AG / Key word(s): Final Results 28.03.2014 / 08:30 Company confirms preliminary financial results for the fiscal year ending December 31, 2013 announced on February 26, 2014 Prior to securing U.S. market approval for Epi proColon(R), Epigenomics provides an outlook for 2014, expecting revenue and net loss slightly increased compared to 2013 FDA Advisory […]
27. March 2014
Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act) Epigenomics AG: FDA Advisory Committee Provides Recommendations for Epigenomics’ Colorectal Cancer Screening Blood Test
Epigenomics AG / Key word(s): Miscellaneous 27.03.2014 02:20 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— FDA Advisory Committee votes favorably that the benefits of Epi proColon(R) outweigh the risks […]
27. March 2014
Epigenomics AG: FDA Advisory Committee Provides Recommendations for Epigenomics’ Colorectal Cancer Screening Blood Test
Epigenomics AG / Key word(s): Regulatory Admission 27.03.2014 / 07:00 FDA Advisory Committee votes favorably that the benefits of Epi proColon(R) outweigh the risks Berlin (Germany) and Germantown, MD (U.S.A.), March 27, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced the outcome of a meeting […]
10. March 2014
Epigenomics and VSA receive approval to market Epi proColon in Argentina
Epigenomics AG / Key word(s): Regulatory Approval 10.03.2014 / 10:00 Epigenomics and VSA receive approval to market Epi proColon in Argentina Berlin (Germany), Germantown, MD (U.S.A.) and Buenos Aires (Argentina) March 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, and VSA ALTA COMPLEJIDAD S.A. (VSA), a […]
05. March 2014
Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs
Epigenomics AG / Key word(s): Study 05.03.2014 / 09:00 Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs – Study conducted using Epigenomics’ Epi proColon(R) 2.0 CE – Results in line with the results achieved in the CE marking study reported in […]